| Document Date: 2013-06-10 17:56:06
Open Document File Size: 3,30 MBShare Result on Facebook
City ADA / / Company Zyngenia Inc. / Millipore / GE Healthcare / Akt / Sepax Technologies Inc. / / Country United States / / / Event Product Issues / / Facility University of Washington / The Skaggs Institute / terminus H-chains / Biopharmacy Core facility / The Scripps Research Institute / / IndustryTerm treatment of inflammatory diseases / phosho3 week untreated control / goat anti-human kappa chain / chip using goat anti-human kappa chain / captured using goat anti-human kappa chain / / MedicalCondition inflammatory response / COPD / Both inflammatory and angiogenic pathways / complex disease / arthritis / arthritic disease / Crohn disease / rheumatoid arthritis / inflammatory cytokine / inflammatory angiogenesis / inflammatory mediators / psoriasis / inflammatory diseases / dissociation / necrosis factor / tumor / delayed type hypersensitivity / cancer / opportunistic infections / disease / increased disease / defective inflammatory response / thioglycollate-induced peritonitis / chronic obstructive pulmonary disease / increased inflammatory response / immune and inflammatory pathways / active disease / tumor necrosis / inflammatory conditions / diseases / chronic arthritis / inflammatory disease / SLE / inflammation / / MedicalTreatment immunosuppression / / NaturalFeature Charles River / / Organization U.S. Securities and Exchange Commission / Skaggs Institute for Chemical Biology / Scripps Research Institute / University of Washington / Seattle / / Person Viktor V. Roschke / Viktor V / Bridget A. Puffer / Palanisamy Kanakaraj / / Position vivo model / mediator / RT / / Product Humira / Herceptin / IL-1R / Remicade / IL-6 / IL-1 / Ang2 / glycine / Tao / mice / inflammatory response / / PublishedMedium Molecular Biology / / Technology electrophoresis / antibodies / Zybody technology / apoptosis / phage display / CM5 chip / performed using specific antibodies / / URL http /
SocialTag |
Report mAbs 4:5, [removed]; September/October 2012; © 2012 Landes Bioscience Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy